The lead T cell therapy program is advancing to phase III for post-transplant relapse prevention in heme malignancies, with strong early efficacy signals and improved manufacturing. The pivotal trial is designed for broad accessibility and regulatory rigor, with regular data updates and financial strategies in place to bridge to top-line results.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.